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Introduction
Adrenocortical carcinoma (ACC) is a rare but aggressive
solid cancer with a 5-year survival rate of \15 % at the
metastatic stage [1]. Surgery remains the only curative
treatment in patients diagnosed at an early stage [1, 2].
Mitotane, is currently the only drug approved in Europe
and in the United States for the treatment of advanced ACC
[2]. As monochemotherapy, a response rate of mitotane
between 13–35 % has been reported [1, 2]. However,
patients achieving a plasma mitotane level above 14 mg/L
show a higher response rate and an improved survival [1,
2]. In combination with chemotherapy, response rates of
mitotane range between 14–55 % [1–3]. No novel treat-
ment option has emerged in the last four decades [1, 2],
underlining the urgent need of new therapeutic options for
patients affected by this malignancy.
The mammalian target of rapamycin (mTOR) pathway is
considered a target for antineoplastic therapy, and in pre-
clinical models of ACC, mTOR inhibitors such as sirolimus,
temsirolimus, and everolimus inhibit cell proliferation in a
dose- and time-dependent manner [4–6]. However, different
human ACC cell lines and primary cultures show a variable
response to mTOR inhibitors [7, 8]. In the absence of a clear
predictor of the effectiveness of mTOR inhibitors in this
malignancy, it is difficult to define selection criteria for
patients, who are candidates for these drugs [1, 7–9].
Therefore, combination of mTOR inhibitors with mitotane
could be a more prudent clinical approach than the use of
these inhibitors as monotherapy in unselected ACC patients.
This study aimed at evaluating the effects of mitotane in
combination with sirolimus in the two human ACC cell
lines H295 and the SW13.
Materials and methods
Two human ACC cell lines the NCI-H295R (H295) and the
SW13, were obtained and cultured as previously described
[7]. Mitotane was purchased from Sigma-Aldrich and dis-
solved in ethanol as a concentrated (10-2 M) stock solution
(stored at -20 C) and diluted in ethanol prior to use. The
mTOR inhibitor sirolimus was obtained from LC Labora-
tories and used as previously described [7]. The doses of
sirolimus used were selected on the bases of the previously
reported dose–response curves of sirolimus in the used cell
lines [7]. The measurement of total DNA content was used
as a measure of cell proliferation and performed as previ-
ously described [7]. For the statistical analysis, statistical
software of GraphPad Prism version 5 (GraphPhad Soft-
ware, San Diego, CA) was used.
Results
In both H295 and SW13, mitotane significantly inhibits cell
proliferation in a dose-dependent manner (Fig. 1). Mito-
tane was slightly, but significantly more potent in H295
(IC50 4.5 9 10
-6 M) than in SW13 (IC501.6 9 10
-5 M)
(p\ 0.01).
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In both H295 and SW13, the selected concentrations of
sirolimus significantly inhibited cell proliferation (24–45 %
and 57–70 %, respectively; p\ 0.001).
When mitotane was used at low concentrations (between
10-7 and 5 9 10-6M), sirolimus had a statistically sig-
nificant additive effect, when compared with mitotane
alone (Fig. 1).
In H295, as compared with sirolimus alone, mitotane at
a concentration higher than 10-7 M had significant addi-
tive effects when combined with both the concentrations of
sirolimus tested (p\ 0.01 or p\ 0.001; Fig. 1a). In SW13,
as compared with sirolimus alone, mitotane had significant
additive effects only when the highest concentration of
mitotane (10-5 M) was combined with the lowest con-
centration of sirolimus (5 9 10-11 M) (p\ 0.05; Fig. 1b).
Discussion
The current study demonstrates that in human ACC cell
lines, sirolimus has additive antiproliferative effects when
combined with low mitotane doses.
Mitotane is a referral drug in the treatment of ACC
patients, but unfortunately there are patients who do not
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Fig. 1 Combined effects of a
6-day treatment with increasing
concentrations of mitotane
(Mito) and selected
concentrations of sirolimus
(S) in two human ACC cell
lines: H295 (panel a) and SW13
(panel b). At some of the
combinations tested significant
additive inhibitory effects on
cell growth are observed in both
cell lines. *p\ 0.05,
**p\ 0.01 and ***p\ 0.001;
xp\ 0.05, xxp\ 0.01 and
xxxp\ 0.001 versus control
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respond and/or tolerate the drug, raising the requirement of
new treatment options [1, 2].
The mitotane therapeutic window is very narrow.
Therefore, monitoring mitotane plasma levels during
treatment is very important. A response rate of up to 66 %
has been reported in patients achieving mitotane plasma
level above 14 mg/L, but a higher rate of adverse effects is
reported when the plasma mitotane level exceeds 20 mg/L.
A rapid achievement and long-term maintenance of this
therapeutic range (14–20 mg/L) has been suggested as a
predictor of mitotane response in patients with ACC [1, 2,
10, 11]. However, this clinical goal is sometimes difficult
to reach because of the complex pharmacokinetic of
mitotane which causes a large variation in individual drug
availability. Additionally, the onset of adverse events can
preclude a fast drug escalation or the use of a high mitotane
dose. Treatment strategies combining mitotane with other
drugs could increase the response rate of patients, as
compared with monotherapy, for several reasons. The
combination could have additive antiproliferative effects
that potentially increase the in vivo antineoplastic effects.
On the other hand, in absence of appropriate predictors of a
clinical response that can help to select patients for the
most appropriate treatment, the combination of two drugs
acting with different mechanisms, could increase the
chance of patients to get a clinical benefit from at least one
of the two treatments. Additionally, in particular in the case
of mitotane, the combined treatment with other active
drugs could reduce the risk of tumor progression during the
treatment initial mitotane dosage titration.
Recently, mTOR inhibitors have been suggested as a
new potential treatment for ACC. Preclinical data suggest
sirolimus, temsirolimus, and everolimus can inhibit ACC
cell proliferation [4–6]. However, preliminary experience
with the use of everolimus as salvage treatment in few
ACC patients did not show promising results [12], whereas
combined treatment of an insulin like growth factor 1
receptor (IGF1R) antibody with temsirolimus in a phase I
study including ACC patients, showed more promising
results [13]. Therefore, combination treatment with mTOR
inhibitors and other drugs might have higher effects than
mTOR inhibitors alone. To our knowledge, there are no
in vitro studies evaluating the effects of mitotane in com-
bination with mTOR inhibitors.
In the current study, all the concentrations of mitotane
used (from 10-7 to 10-5 M) were lower than the concen-
trations (4.3–6.3 9 10-5 M) corresponding to the mitotane
plasma level at the therapeutic range [14]. The addition of
sirolimus to these low concentrations of mitotane showed
higher antiproliferative effects than mitotane alone sug-
gesting that combined treatment might have additive
effects to the antineoplastic action of mitotane, permitting
to reduce the dose required to obtain desired clinical
effects. This additivity was higher when the concentration
of mitotane used were lower, suggesting that combined
treatment might be particularly useful during the phases of
treatment in which mitotane plasma level are below the
therapeutic range, such as during the initial dose titration
and/or for those patients in which the therapeutic range of
mitotane is hardly maintained due to low tolerance or other
reasons.
With the exception of 10-6 M sirolimus used in H295
cells, all the tested concentrations where within the range of
blood drug levels reached in humans during sirolimus
treatment (maximal concentration about 10-7 M) [15, 16].
In both cell lines, the addition of mitotane to sirolimus
showed a significant additive inhibitory effect as compared
with sirolimus alone, but only at some of the experimental
conditions tested. Particularly, in SW13 cells that are more
sensitive to sirolimus, but less sensitive to mitotane than
H295, the addition of mitotane showed a significant additive
inhibitory effect as compared to sirolimus alone, only when
the highest mitotane concentration was combined with a
very low sirolimus concentration. This might be related to
the potent inhibitory effects of sirolimus alone in SW13
cells, which induced already a near maximal inhibition of
cell proliferation. While H295 cells are well accepted as a
good model of ACC, a debate is still open about the
appropriateness of SW13 cells as a model for this type of
cancer [17]. Taking the other potential limitations of ACC
cell lines as preclinical model of ACC, the results of the
current study might suggest that among ACC patients it
could be possible to find a subgroup of patients with a high
sensitivity to sirolimus, in which the use of combined
treatment could induce an important antineoplastic effect
even in the absence of mitotane effect, such as in mitotane-
resistant patients.
Among the potential limitations of the current study,
there is the lack of possibility to explore pharmacokinetic
interactions between drugs. In the in vivo setting, mitotane
is a well known inducer of microsomal liver enzyme
cytochrome P450 (CYP3A4/5) [18]. The induction of this
enzyme can reduce the circulating concentrations of drugs
metabolized by it, including mTOR inhibitors [19]. This
pharmacokinetic interaction should be kept in mind when
translating the in vitro results to the potential in vivo
applications, and attention should be used in monitoring the
blood concentrations of drugs to reach the desired thera-
peutic levels.
In conclusion, this study suggests a potential advantage
of combining mitotane with sirolimus, but these data are
still preliminary. Clearly, additional studies, including
animal models, are mandatory before moving from the
bench to the bedside.
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